dr. Ken Kersemans (PhD)

CRIG member
Ken Kersemans


R&D supervisor – Cyclotron, Department of Nuclear Medicine (UZ Gent) 
 

Research focus

Ken Kersemans is responsible for the R&D efforts at the cyclotron of the department of Nuclear Medicine (UZGent) where he is responsible for the implementation and validation of state of the art imaging probes in the clinic.
Recent projects in which he is strongly involved include:

  • the automated radiosynthesis and clinical evaluation of 18F-PSMA-11 (prostate cancer imaging),
  • the development of radiolabelled microspheres for the prediction of microsphere biodistribution (radiotherapy) and
  • the development of a new LAT-1 specific radiofluorinated phenylalanine analog (18F-FELP) for brain tumor imaging.

His main interests are within the field of radiochemistry, radiopharmacy, and (clinical) molecular imaging.
 

Biography

In 2003 Ken Kersemans obtained his Master's degree in Analytical Chemistry and in 2010 he graduated from the Free University of Brussels (VUB) with a PhD in Chemistry (grade: "summa cum laude"). His doctoral research focused on the development of novel radiofluorinated alkylphenylalanine analogs for tumor imaging with positron emission tomography (PET). During his time as a doctoral student, he gained experience in the field of organic chemistry, radiochemistry, and quantum chemistry and gained insight in the preclinical evaluation of novel PET tracers and molecular imaging. 

From 2010-2015 he took the position of Post-Doctoral Assistant at the University of Ghent, Belgium, where he continued his work on amino acid based tumor tracers. Other research projects in which he was involved focused on the radiosynthesis of novel radiolabeled probes for oncology and neurosciences, preclinical drug development and the quantification of the immobilization of various radiolabeled biopolymers on functionalized biomaterials. 

At this moment, Ken Kersemans is responsible for the R&D efforts at the cyclotron of the department of Nuclear Medicine (UZGent) where he is responsible for the implementation and validation of state of the art imaging probes in the clinic. 
 

Key publications

  • Hypoxia imaging with 18F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts. December 2018; Radiation Oncology 13(1); DOI: 10.1186/s13014-018-0984-3.
  • Evaluating Hepatobiliary Transport with 18 F-Labeled Bile Acids: The Effect of Radiolabel Position and Bile Acid Structure on Radiosynthesis and In Vitro and In Vivo Performance. April 2018; Contrast Media & Molecular Imaging 2018(8):1-9; DOI: 10.1155/2018/6345412.
  • Automated radiosynthesis of Al[ 18 F]PSMA-11 for large scale routine use. January 2018; Applied Radiation and Isotopes 135; DOI: 10.1016/j.apradiso.2018.01.006.
  • PET for Therapy Response Assessment in Glioblastoma. September 2017; DOI: 10.15586/codon.glioblastoma.2017.ch10. In book: Glioblastoma.
  • Finding the appropriate tool for the accurate prediction of microsphere biodistribution: SIR-Spheres radiolabelled with 18F, 111In and 99mTc. June 2017; Conference: SNMMI 2017; At: Denver (USA).

     

Contact & links

  • Lab Address: Department of Nuclear Medicinecampus UZ Gent, Corneel Heymanslaan 10, 9000 Ghent, Belgium
  • ResearchGate 
  • Ken Kersemans is interested to receive invitations for presentations or talks